Compare DexCom, Inc. (DXCM) vs Gap Inc (GAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Gap Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Gap Inc trades at $23.33 (market cap $8.21B). The key difference: DexCom, Inc. is far larger — about 3.9× Gap Inc's market cap, and Gap Inc pays a 3% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Gap Inc for 37 Days on average.
| DXCM | GAP | |
|---|---|---|
Market Cap | $31.86B | $8.21B |
Volume | 3,607,070 | 5,192,917 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $29.13 |
52-Week Low | $54.84 | $18.35 |
Typical Hold Time | 62 Days | 37 Days |
Enterprise Value | $31.32B | $11.44B |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
Gap (GAP) trades at $23.61, down 0.76% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 7.11 and robust profitability, including a 33.78% ROE. Recent earnings beat estimates in Q1 and Q2 2026, and the company is expanding into music partnerships to engage customers. Cash flow from operations remains healthy at $1.49 billion for 2025.
The outlook is positive given Gap's attractive valuation, earnings momentum, and strategic initiatives. Key risks include competitive pressures in retail and reliance on brand revitalization. Analyst consensus is a $25.67 price target, suggesting upside potential, but investors should monitor execution of growth strategies amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
